Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.52 |
| ▸ | MMP9 | P14780 | 10/20 | 0.52 |
| ▸ | MMP13 | P45452 | 2/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
| ▸ | MMP7 | P09237 | 1/20 | 0.52 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.51 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037885 | 1.00 | MMP2 (0.52) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL5037620 | 0.88 | MMP2 (0.53) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL5037617 | 0.88 | MMP2 (0.53) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL4269569 | 0.84 | MMP2 (0.66) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL5047244 | 0.82 | MMP2 (0.53) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL5042554 | 0.73 | MMP2 (0.49) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL4425847 | 0.72 | MMP13 (0.65) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL27542487 | 0.72 | MMP13 (0.65) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL6545297 | 0.71 | MMP2 (1.00) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL1920507 | 0.71 | MMP2 (1.00) | MMP2MMP9MMP13MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248937-A1 | Substituted phenylalkanoic acids for the treatment of diabetes | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2004-12-09 | — | — | US | claimed |
| EP-1633354-B1 | N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES | INST FOR PHARM DISCOVERY INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20040248937-A1 | Substituted phenylalkanoic acids for the treatment of diabetes | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248937-A1 | Substituted phenylalkanoic acids for the treatment of diabetes | PTP4A1, PTPRJ, PPM1B | MMP2 3270/4885MMP9 4031/4885MMP13 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.